Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | STS | P08842 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22518586 | 0.94 | HPGD (0.56) | RECQLUSP2SMN1; SMN2HPGDGPR119 | |
| SCHEMBL29014961 | 0.90 | RECQL (0.49) | RECQLUSP2SMN1; SMN2HPGDGPR119 | |
| Methane SCHEMBL28121361 | 0.86 | HPGD (0.54) | RECQLUSP2SMN1; SMN2HPGDGPR119 | |
| SCHEMBL56404 | 0.85 | HPGD (0.53) | RECQLUSP2SMN1; SMN2HPGDGPR119 | |
| SCHEMBL56603 | 0.85 | HPGD (0.53) | RECQLUSP2SMN1; SMN2HPGDGPR119 | |
| SCHEMBL1514778 | 0.83 | EPHX1 (0.52) | RECQLUSP2SMN1; SMN2HPGDGPR119 | |
| SCHEMBL32667629 | 0.83 | HPGD (0.51) | RECQLUSP2SMN1; SMN2HPGDGPR119 | |
| SCHEMBL4183086 | 0.82 | NR1H2 (0.50) | RECQLUSP2SMN1; SMN2HPGDGPR119 | |
| SCHEMBL2146006 | 0.82 | HPGD (0.47) | RECQLUSP2SMN1; SMN2HPGDGPR119 | |
| SCHEMBL56423 | 0.82 | HPGD (0.50) | RECQLUSP2SMN1; SMN2HPGDGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112225722-A | Method for preparing crizotinib intermediate by using microchannel reactor | 张家港威胜生物医药有限公司 | 2021-01-15 | — | — | CN | claimed |
| CN-112752757-B | Tyrosine amide derivatives as RHO-kinase inhibitors | 奇斯药制品公司 | 2024-01-12 | — | — | CN | disclosed |
| WO-2023199238-A1 | NOVEL COMPOUNDS TO TREAT CYTOKINE RELATED DISORDERS | ZYDUS LIFESCIENCES LIMITED (IN) | 2023-10-19 | — | — | WO | disclosed |
| WO-2023199238-A1 | NOVEL COMPOUNDS TO TREAT CYTOKINE RELATED DISORDERS | ZYDUS LIFESCIENCES LIMITED (IN) | 2023-10-19 | — | — | WO | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| CN-113677664-A | Tricyclic degradants of IKAROS and AIOLOS | C4医药公司 | 2021-11-19 | — | — | CN | disclosed |
| WO-2021127586-A1 | PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2021-06-24 | — | — | WO | disclosed |
| CN-112225722-A | Method for preparing crizotinib intermediate by using microchannel reactor | 张家港威胜生物医药有限公司 | 2021-01-15 | — | — | CN | disclosed |
| US-9943519-B2 | Pharmaceutical compounds | GENENTECH, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| CN-104662018-B | Substituted Heterobicyclic compounds, composition and its medical applications | 阿迪维纳斯治疗有限公司 | 2017-10-24 | — | — | CN | disclosed |
| CN-1326444-A | Process for the synthesis of intermediates useful in the preparation of tricyclic compounds | SCHERING CORP (US) | 2001-12-12 | — | — | CN | disclosed |
| US-6307048-B1 | Enantioselective alkylation of tricyclic compounds | SCHERING CORPORATION | 2001-10-23 | — | — | US | disclosed |
| EP-1131296-A2 | SYNTHESIS OF INTERMEDIATES USEFUL IN PREPARING TRICYCLIC COMPOUNDS | SCHERING CORPORATION (US) | 2001-09-12 | — | — | EP | disclosed |
| EP-1131313-A1 | ENANTIOSELECTIVE ALKYLATION OF TRICYCLIC COMPOUNDS | SCHERING CORPORATION (US) | 2001-09-12 | — | — | EP | disclosed |
| US-6288233-B1 | Enantioselective alkylation of tricyclic compounds | SCHERING CORPORATION | 2001-09-11 | — | — | US | disclosed |
| WO-2000031064-A1 | ENANTIOSELECTIVE ALKYLATION OF TRICYCLIC COMPOUNDS | SCHERING CORPORATION (US) | 2000-06-02 | — | — | WO | disclosed |
| WO-2000030589-A2 | SYNTHESIS OF INTERMEDIATES USEFUL IN PREPARING TRICYCLIC COMPOUNDS | SCHERING CORPORATION (US) | 2000-06-02 | — | — | WO | disclosed |
| CN-1222153-A | Piperidine acetic acid derivatives and their use in the treatment of thrombotic disorders | GLAXO GROUP LTD (GB) | 1999-07-07 | — | — | CN | disclosed |
| EP-0912555-A1 | PIPERIDINE ACETIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997049699-A1 | PIPERIDINE ACETIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 1997-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | CRBN, IKZF1, IKZF3 | RECQL 1432/4885USP2 159/4885SMN1; SMN2 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.